{"id":"W4292002773","doi":"10.17650/1726-9776-2022-18-2-39-57","title":"Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study","year":2022,"lang":"en","type":"article","venue":"Cancer Urology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University","funders":"","keywords":"Lenvatinib; Medicine; Everolimus; Pembrolizumab; Sunitinib; Renal cell carcinoma; Oncology; Internal medicine; Quality of life (healthcare); Sorafenib; Cancer; Immunotherapy; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001401932,0.001040782,0.002679576,0.0003393751,0.0004084352,0.0008157367,0.0007282149,0.001222257,0.003136286],"category_scores_gemma":[0.001334156,0.0004958457,0.002691424,0.0005247609,0.0008016365,0.0008926925,0.0005076111,0.002769473,0.0003913429],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001100407,"about_ca_system_score_gemma":0.0009685169,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00167669,"about_ca_topic_score_gemma":0.003120157,"domain_scores_codex":[0.9991374,0.0004908976,0.00004853133,0.0001374845,0.00007182234,0.0001139395],"domain_scores_gemma":[0.99889,0.0002718565,0.0003314969,0.00005435522,0.00006149129,0.0003908945],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9765528,0.00539437,0.002968563,0.0004204675,0.002011049,0.00002108904,0.0000431333,0.00038205,0.001274704,0.00003772853,0.0004030991,0.01049091],"study_design_scores_gemma":[0.8568761,0.1226806,0.01756246,0.00004250558,0.001442926,0.00003829735,0.00004109838,0.0004268499,0.0002911445,0.0001161763,0.0004606646,0.00002131001],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9944813,0.003267496,0.0001242866,0.0002435149,0.0001344984,0.0005953762,0.0004758222,0.00001749414,0.0006601363],"genre_scores_gemma":[0.9961793,0.001136853,0.0003426467,0.0003458444,0.0001699095,0.000734588,0.0006014416,0.000005199092,0.0004841796],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003136286,"threshold_uncertainty_score":0.01049191,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05226541449896924,"score_gpt":0.333492476274445,"score_spread":0.2812270617754757,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}